Himalaya Nutravedics India IPO: In-Depth Analysis, Dates, and Financial Outlook
The highly anticipated Himalaya Nutravedics India IPO is gearing up to hit the BSE SME platform, offering a unique opportunity for investors looking to participate in the growing Ayurvedic and nutraceutical manufacturing sector. With a strong track record of impressive financial growth over a short operating history, the company presents a compelling case for the market.
In this comprehensive guide, we provide a detailed analysis of the upcoming public issue, covering essential dates, business operations, financial metrics, valuation, and an objective SWOT analysis to help you make an informed decision.
What Does Himalaya Nutravedics India Ltd Do?
Incorporated recently in June 2022, Himalaya Nutravedics India Limited has rapidly established itself as a prominent player in the health and wellness sector. Based in Hyderabad, the company specializes in formulating, manufacturing, and marketing a diverse range of Ayurvedic and nutraceutical products.
- Diverse Product Portfolio: Their offerings include Softgel Capsules, Tablets, Medicated Oils, Liquid Orals, Hardgel Capsules, and Protein Powders.
- Therapeutic Focus: The company targets critical healthcare segments such as digestive health, immunity boosting, metabolic health, and pain management.
- Business Model: Rather than relying solely on mass marketing, the company focuses on doctor acceptance, promoting branded products through healthcare practitioners. They also undertake third-party contract manufacturing.
- Infrastructure & Reach: Himalaya Nutravedics boasts an integrated manufacturing facility in Hyderabad holding prestigious certifications including ISO 22000:2018, ISO 9001:2015, and WHO-GMP. They currently operate across 17 states and one union territory in India.
Himalaya Nutravedics IPO Details
The company plans to raise ₹26.50 Crores through a completely fresh issue of 24.99 lakh shares. Below is the structured breakdown of the core offering parameters.
| Parameter | Details |
|---|---|
| IPO Open Date | September 22, 2026 |
| IPO Close Date | September 24, 2026 |
| Face Value | ₹10 per equity share |
| Price Band | ₹100 to ₹106 per share |
| Lot Size | 1,200 Shares |
| Total Issue Size | 24,99,600 shares (Aggregating up to ₹26.50 Cr) |
| Issue Type | Book Built Issue |
| Listing Exchange | BSE SME |
IPO Timeline & Progress Tracker
Keeping track of key dates is vital for prospective investors. Below is the expected schedule for the subscription, allotment, and listing.
| Event | Tentative Date |
|---|---|
| Bid Opening Date | Tuesday, September 22, 2026 |
| Bid Closing Date | Thursday, September 24, 2026 |
| Finalization of Basis of Allotment | Friday, September 25, 2026 |
| Initiation of Refunds / Credit of Shares | Monday, September 28, 2026 |
| Listing on BSE SME | Tuesday, September 29, 2026 |
Lot Size and Investment Requirements
Retail and High Net-worth Individuals (HNIs) must adhere to specific minimum and maximum lot sizes while applying for this SME IPO. Interestingly, the minimum application size for retail investors in this issue mandates 2 lots.
| Investor Category | Minimum Lots | Total Shares | Amount Required (at upper band) |
|---|---|---|---|
| Retail (Min) | 2 | 2,400 | ₹2,54,400 |
| Retail (Max) | 2 | 2,400 | ₹2,54,400 |
| S-HNI (Min) | 3 | 3,600 | ₹3,81,600 |
| S-HNI (Max) | 7 | 8,400 | ₹8,90,400 |
| B-HNI (Min) | 8 | 9,600 | ₹10,17,600 |
Financial Performance Overview
The company has showcased remarkable growth metrics over the last three fiscal years. Notably, the total revenue has witnessed a massive surge, and profitability margins have significantly improved. Here is a look at the restated consolidated financials.
| Financial Metric (₹ in Crores) | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Total Assets | 6.09 | 10.82 | 24.42 |
| Total Income | 14.43 | 21.00 | 43.12 |
| Profit After Tax (PAT) | 0.43 | 2.23 | 7.39 |
| EBITDA | 0.94 | 2.99 | 8.10 |
| Net Worth | 1.34 | 6.75 | 16.38 |
| Total Borrowings | 3.24 | 1.76 | 5.13 |
Company Valuation & Key Performance Indicators (KPIs)
Understanding the valuation metrics is critical to assessing whether the IPO is priced attractively.
| Metric | Value (As of FY26) |
|---|---|
| Pre-IPO EPS | ₹11.72 |
| Post-IPO EPS | ₹8.39 |
| Price-to-Earnings (P/E) Pre-IPO | 9.04x |
| Price-to-Earnings (P/E) Post-IPO | 12.63x |
| Return on Equity (ROE) | 63.87% |
| Return on Capital Employed (ROCE) | 36.41% |
| Debt to Equity Ratio | 0.31 |
| PAT Margin | 17.16% |
Promoter Holdings & Objective of the Issue
The company is led by a strong promoter group comprising Rohit Asawa, Divya Asawa, Chanda Asawa, and Rama Raju Penmatsas.
- Pre-Issue Promoter Holding: 95.14%
- Post-Issue Promoter Holding: 69.94%
Why is the Company Raising Funds?
The net proceeds from this fresh issue (approximately ₹21.25 Cr after issue expenses) will be deployed as follows:
- Funding Working Capital Requirements: ₹13.75 Crores
- Business Development & Digital Marketing: ₹7.50 Crores
- General Corporate Purposes: Balance amount.
Note: Data regarding anchor investor participation has not been formally announced at the time of compiling this report.
SWOT Analysis of Himalaya Nutravedics
Strengths
- Integrated multi-dosage manufacturing capabilities with global quality certifications (WHO-GMP).
- Exceptional financial ratios (ROE of 63.87% and ROCE of 36.41%).
- Strong B2B network driving doctor acceptance.
Weaknesses
- Relatively short operating history, having been incorporated only in 2022.
- Geographical concentration risks, despite expansion to 17 states.
Opportunities
- The post-pandemic shift toward Ayurveda and preventive health supplements.
- Allocation of ₹7.50 Cr for digital marketing opens direct-to-consumer (D2C) online revenue streams.
Threats
- High fragmentation and aggressive competition in the Indian nutraceutical space.
- Strict regulatory shifts regarding Ayurvedic product claims and manufacturing compliances.
Registrar and Lead Manager Details
Investors requiring assistance regarding allotment status or application discrepancies can reach out to the official registrar:
- Registrar: Kfin Technologies Ltd.
- Email: himalaya.ipo@kfintech.com
- Phone: 040-79615565
Book Running Lead Manager: Nirbhay Capital Services Pvt. Ltd.
Company Contact Information
Himalaya Nutravedics India Ltd.
Plot No. 101/A, Phase-III, Industrial Development Park,
Cherlapally, Hindustan Cables Ltd, Uppal,
Hyderabad, Telangana, 500051
Phone: +91-9063498493
Email: info@himalayanutravedics.com
Conclusion
The Himalaya Nutravedics India IPO brings forward an enterprise operating in the high-growth sector of Ayurvedic and nutraceutical products. Supported by stellar margin expansions, minimal debt (D/E of 0.31), and certified manufacturing infrastructure, the company exhibits promising fundamental strength. However, the relatively short operating history and the high minimum investment threshold for retail participants (₹2.54 Lakhs) are factors that require careful consideration.
Prospective investors should weigh the impressive financial momentum against sector-specific risks and overall market sentiment before making participation decisions.